Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
HAE - Haemonetics Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$75.33
DETAILS
HIGH:
$89.00
LOW:
$67.00
MEDIAN:
$70.00
CONSENSUS:
$75.33
UPSIDE:
15.03%
Stock News
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? GF Value Says Undervalued
On May 21, 2026, Haemonetics Corp (HAE) shares rose 4.0%, bringing the current price to $61.94. The stock has fluctuated significantly over the past year, with
Is the Options Market Predicting a Spike in Haemonetics Stock?
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Q4 Earnings Call Highlights
Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.
The London Company Small Cap Portfolio Q1 2026 Portfolio Review
Matson was the top performer as container shipping rates strengthened amid supply chain disruptions and management executed on operational efficiency initiatives. Revolve Group sold off as the online fashion retailer faced softer consumer demand and lower discretionary spending. We added to Haemonetics Corporation following recent share price volatility.
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Haemonetics to Present at Bank of America 2026 Healthcare Conference
BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:00 a.m. PT. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/75d0U1.cfm.
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was published earlier this week in the Journal of Cardiovascular Electrophysiology.
Analyzing Bio-Rad Laboratories (NYSE:BIO) & Haemonetics (NYSE:HAE)
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Risk and Volatility Bio-Rad Laboratories has a beta
Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review
Haemonetics (NYSE: HAE - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Risk and Volatility Haemonetics has a beta of 0.36,
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026.
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) to treat atrial fibrillation.
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Invenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter. The quarter-end position value decreased by $24.29 million due to the sale of all the fund's shares.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Price Targets
Haemonetics price target lowered to $89 from $94 at Barrington
$89.00
(was $52.24)
Barrington
Haemonetics price target lowered to $67 from $72 at Baird
$67.00
(was $51.55)
David Rescott
·
Robert W. Baird
Haemonetics price target lowered to $70 from $80 at Mizuho
$70.00
(was $57.39)
Anthony Petrone
·
Mizuho Securities
Haemonetics price target lowered to $81 from $99 at Baird
$81.00
(was $61.40)
Robert W. Baird
Haemonetics price target raised to $94 from $93 at Barrington
$94.00
(was $65.02)
Barrington
Haemonetics price target lowered to $80 from $90 at Mizuho
$80.00
(was $65.02)
Mizuho Securities
Haemonetics price target raised to $93 from $90 at Barrington
$93.00
(was $82.03)
Barrington
Haemonetics price target raised to $90 from $75 at Mizuho
$90.00
(was $81.11)
Mizuho Securities
Haemonetics price target raised to $99 from $87 at Baird
$99.00
(was $80.33)
Robert W. Baird
Haemonetics (HAE) PT Raised to $90 at Raymond James
$90.00
(was $73.91)
Andrew Cooper
·
Raymond James
Haemonetics price target raised to $88 from $85 at BTIG
$88.00
(was $66.20)
BTIG
Haemonetics price target lowered to $68 from $84 at Needham
$68.00
(was $55.64)
Mike Matson
·
Needham
Raymond James Upgrades Haemonetics (HAE) to Strong Buy
$120.00
(was $74.83)
Andrew Cooper
·
Raymond James
Haemonetics initiated with a Buy at CL King
$116.00
(was $73.26)
Kristen Stewart
·
C.L. King
BofA Securities Starts Haemonetics (HAE) at Neutral
$85.00
(was $71.61)
Craig Bijou
·
Bank of America Securities
Needham Upgrades Haemonetics (HAE) to Buy
$112.00
(was $83.41)
Mike Matson
·
Needham